

A novel protocol to derive cervical motor neurons from induced pluripotent stem cells for amyotrophic lateral sclerosis

Meimei Yang,^{1,2,10} Min Liu,^{3,10} Yajaira Feller Sánchez,⁴ Sahar Avazzadeh,⁴ Leo R. Quinlan,⁴ Gang Liu,⁵ Yin Lu,⁶ Guangming Yang,⁷ Timothy O'Brien,¹ David C. Henshall,^{2,8,*} Orla Hardiman,^{2,9,*} and Sanbing Shen^{1,2,*}

¹Regenerative Medicine Institute, School of Medicine, University of Galway, H91 W2TY Galway, Ireland

²FutureNeuro SFI Research Centre for Chronic and Rare Neurological Diseases and Department of Physiology & Medical Physics, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland

³Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory of Molecular and Cellular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, China

⁴Cellular Physiology Research Laboratory and CÚRAM SFI Centre for Research in Medical Devices, School of Medicine, University of Galway, H91 TK33 Galway, Ireland

⁵Department of Cardiology, The First Hospital of Hebei Medical University, Hebei Key Laboratory of Cardiac Injury Repair Mechanism Study, Hebei Key Laboratory of Heart and Metabolism, Hebei Engineering Research Center of Intelligent Medical Clinical Application, Hebei International Joint Research Center for Structural Heart Disease, Shijiazhuang, Hebei, China

⁶College of Pharmacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China

⁷College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China

⁸Department of Physiology and Medical Physics, RCSI University of Medicine & Health Sciences, D02 YN77 Dublin, Ireland

⁹Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, Ireland

¹⁰These authors contributed equally

*Correspondence: dhenshall@rcsi.ie (D.C.H.), hardimao@tcd.ie (O.H.), sanbing.shen@universityofgalway.ie (S.S.)

<https://doi.org/10.1016/j.stemcr.2023.07.004>

SUMMARY

Sporadic amyotrophic lateral sclerosis (sALS) is the majority of ALS, and the lack of appropriate disease models has hindered its research. Induced pluripotent stem cell (iPSC) technology now permits derivation of iPSCs from somatic cells of sALS patients to investigate disease phenotypes and mechanisms. Most existing differentiation protocols are time-consuming or low efficient in generating motor neurons (MNs). Here we report a rapid and simple protocol to differentiate MNs in monolayer culture using small molecules, which led to nearly pure neural stem cells in 6 days, robust OLIG2⁺ pMNs (73%–91%) in 12 days, enriched CHAT⁺ cervical spinal MNs (sMNs) (88%–97%) in 18 days, and functionally mature sMNs in 28 days. This simple and reproducible protocol permitted the identification of hyperexcitability phenotypes in our sALS iPSC-derived sMNs, and its application in neurodegenerative diseases should facilitate *in vitro* disease modeling, drug screening, and the development of cell therapy.

INTRODUCTION

Since the establishment of human induced pluripotent stem cell (iPSC) technology in 2007 (Takahashi et al., 2007), iPSCs have been widely used in regenerative medicine and disease modeling. iPSCs can self-renew and differentiate into almost any cell types in the body, including disease-relevant ones. Motor neuron diseases (MNDs) include amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and spinal and bulbar muscular atrophy and are fatal diseases characterized by degeneration of MNs in the CNS. There is no effective treatment for MNDs, which is thought, in part, to be caused by the lack of suitable human disease models (Hardiman et al., 2017). The development of a robust protocol for derivation of functional MNs is, therefore, crucial for understanding disease mechanisms and developing novel therapies for MNDs.

Spinal MNs (sMNs) are responsible for transmitting commands from the CNS to muscles to control motor activity appropriately. Signaling pathways and transcrip-

tion factors contributing to the sMN development have been unveiled (Jessell, 2000; Muñoz-Sanjuán and Brivanlou, 2002; Shirasaki and Pfaff, 2002; Stifani, 2014). For example, neuroectoderm is activated in the fibroblast growth factor (FGF) and WNT pathways and/or inhibited by bone morphogenetic protein (BMP) and transforming growth factor- β (TGF- β) signalings (De Robertis, 2006; Nordström et al., 2002). Retinoid acid (RA) and sonic hedgehog (SHH) serve as morphogens for the rostrocaudal and dorsoventral axes along the spinal cord (Mühr et al., 1999; Patani et al., 2011; Roelink et al., 1995), which define MN progenitor (pMN) domain and repress other progenitor domains, by co-expressing transcription factors of PAX6 (neuroectodermal markers), NKX6.1 (ventral progenitor marker), and OLIG2 (a pMN-specific marker) (Sagner and Briscoe, 2019). OLIG2 promotes MN development by directly repressing *HES* expression, which in turn induces *NGN2* (Sagner et al., 2018). *NGN2* is required for cell cycle exit and induction of terminal MN transcription factors including *MNX1*, *ISL1*,



and LHX3, to establish MN identity (Lee et al., 2005; Novitsch et al., 2001). MNX1⁺ MNs further differentiate into mature MNs expressing choline acetyltransferase (CHAT), which synthesizes acetylcholine for signal conduction at neuromuscular junctions (Stifani, 2014). The stage-specific MN genes and their expression patterns during development can be used as indicators for *in vitro* differentiation.

Previously, several protocols for sMN differentiation have been developed by mimicking *in vivo* neurogenesis using extrinsic signaling molecules (Figure S1 and Table S1). Different doses, timing, and delivery procedures of signaling molecules among different protocols led to substantial variations in the duration (1–2 months) and efficiency (30%–90%) of MN differentiation. In addition, the derived MNs were often immature, and a lengthy maturation period was required before the detection of electrophysiological activity (Figure S1). As most MNDs including ALS are late-onset diseases, these deficiencies limit the value of the iPSC-derived MNs in revealing disease characteristics.

In this study, we developed an efficient strategy to differentiate iPSCs into cervical sMNs under a monolayer-adherent condition. This protocol can shorten the duration required to detect electrophysiological phenotypes in ALS cell models, by generating nearly pure neural stem cells (NSCs) in 6 days, robust pMNs in 12 days, enriched CHAT⁺ sMNs in 18 days, and functional sMNs with extensive network activities in 28 days. This novel MN differentiation protocol, therefore, facilitates the production of mature sMNs for MND research, high-throughput drug screening, and potential cell transplantation therapy.

RESULTS

Homogeneous caudal and ventral NSCs are generated in 6 days

Dual SMAD inhibition of BMP and TGF- β signaling is widely used in neural induction to generate rostral NSCs (Chambers et al., 2009) expressing *OTX2*, a rostral marker for the fore- and midbrain. However, WNT activation is required for generating NSCs with a caudal fate expressing *HOX* genes (Chambers et al., 2009; Nordström et al., 2002). We therefore in this study first neutralized human iPSCs for 6 days with 2 μ M SB431542 (SB) to inhibit TGF- β signaling, 2 μ M DMH1 to inhibit BMP pathway, and 3 μ M CHIR99021 (CHIR) to activate WNT signaling (Figure 1A) (days 0–6). This resulted in the production of homogeneous NSCs, which were positive for NSC markers of *NESTIN* (96.6% \pm 2.7%), *PAX6* (91.9% \pm 4.3%), and *SOX2* (97.8% \pm 2.1%), but negative for pluripotency marker of *OCT4* (Figures 1B and 1C). The consistent efficiency of NSC derivation was validated in three control and four sALS iPSC lines (Fig-

ure S2A). Reverse transcriptase qPCR (RT-qPCR) results further confirmed high expression of *NESTIN*, *PAX6*, and *SOX2*, but repression of *OCT4* mRNA (Figure 1D).

In addition, this triple treatment was found to significantly caudalize the NSCs, and this was supported by marked activation of *HOXB4* and *HOXC5*, and decreased expression of *OTX2* compared with conventional dual SMAD inhibition (SB + DMH1) (Figures 1E and 1F). The derived NSCs also displayed ventral feature, with induced expression of *NKX6.1* (a ventral progenitor marker) and *OLIG2* (an MNP-specific gene) (Figures 1G and S2B). Thus, the combination of dual SMAD inhibition with WNT activation effectively converted human iPSCs into homogeneous caudal and ventral NSCs in 6 days.

Robust MNPs are derived in 12 days of iPSC differentiation

To convert the NSCs into MNPs, 0.1 μ M RA and 0.5 μ M purmorphamine (an SHH agonist) were applied to the 6-day NSCs for the subsequent 6 days in addition to 1 μ M CHIR + 2 μ M SB + 2 μ M DMH1 (Figure 1A) (days 6–12) (Du et al., 2015). The cell cultures were evaluated on day 12 for the expression of *OLIG2* (an MNP marker), *NKX6.1* (a ventral progenitor marker), *PAX6*, *NKX2.2* (an interneuron progenitor marker), and *PAX7* (a dorsal progenitor marker) to define the pMN domain according to spinal cord development (Sagner and Briscoe, 2019) (Figure S2C).

In the day 12 cultures, 81.5% \pm 6.9% cells were positive for *OLIG2*⁺ (up to 91.4% \pm 1.4%) and 94.3% \pm 0.7% positive for *NKX6.1*⁺ (up to 99.0% \pm 0.5%), whereas only 2.8% \pm 1.5% of cells were positive for *NKX2.2* (Figures 2A–2C). The high efficiency of ventral MNP production was consistently validated in seven individual iPSC lines from six donors (Figure S2B). Additionally, RT-qPCR data confirmed the elevated expression of MNP markers of *OLIG2*, *NKX6.1*, and *PAX6* as well as repression of a dorsal marker *PAX7*. Enhanced expression of *NGN2*, a transcription factor critical for post-mitotic MN induction (Lee et al., 2005; Novitsch et al., 2001), was also observed in the differentiated cells (Figure 2D). Together, these data showed robust derivation of MNPs in 12 days of iPSC differentiation, by treating monolayer iPSCs with 6 days of CHIR + SB + DMH1 and subsequent 6 days of CHIR + SB + DMH1 + RA + purmorphamine.

Compound E effectively promotes the conversion of MNPs into sMNs

In the pMN domain, *OLIG2*-expressing MNPs can become MNs or oligodendrocytes (Lu et al., 2002; Zhou and Anderson, 2002). Therefore, a timely conversion of *OLIG2*⁺ MNPs into MNs is vital to increase MN productions *in vitro*. Notch activity is known to promote MNP proliferation via γ -secretase cleavage, which releases the Notch




Figure 1. Combination of dual SMAD inhibition with WNT activation converts human iPSCs into caudal/ventral NSCs in 6 days

(A) Schematic diagram of the MN differentiation protocol from iPSCs.

(B) Representative images of NESTIN⁺/PAX6⁺ and SOX2⁺/OCT4⁻ NSCs generated after 6 days of SB + DMH1 + CHIR treatment.

(C) The proportion of NESTIN⁺, PAX6⁺, and SOX2⁺ cells on day 6 of differentiation, N = 7 cell lines, n = 3 replicates.

(D) RT-qPCR analysis of *NESTIN*, *PAX6*, *SOX2* and *OCT4* mRNA expression after 6 days of SB + DMH1+CHIR treatment, N = 2, n = 3.

(E) CHIR-induced WNT activation conferred a caudal identity of the NSCs expressing fore/midbrain marker *OTX2* and hindbrain/spinal markers of *HOXB4* and *HOXC5*. N = 4, n = 3.

(F) The NSCs were positively immunostained for a ventral marker NKX6.1 after 6 days of SB + DMH1+CHIR treatment.

(G) RT-qPCR analysis showed activation of *NKX6.1* and *OLIG2* mRNA by addition of CHIR, N = 1, n = 3. All representative images were from the control line of ALSH84C5, Scale bar, 100 μM.

See also [Figure S2](#).

intracellular domain and activates expression of genes including *HES5*, a repressor of proneural genes (Ben-Shushan et al., 2015). We therefore used a γ -secretase inhibitor, Compound E, to inhibit *HES5* expression and accelerate MN differentiation.

We first examined the time course of *OLIG2* expression to determine the optimal time for Compound E treatment, and found *OLIG2* expression was peaked at day 10 (83.3% \pm 6.9%) and 12 (80.2% \pm 7.7%) at both mRNA and protein levels (Figures 3A, 3B, and S3A), and

this was also accompanied by increased *HES5* expression (Figure 3B). Therefore, we chose day 9 (before the peak) and day 12 (at the plateau) to test the effect of Compound E (0.1 μM). We also increased RA to 0.5 μM as a high concentration of RA was shown to induce neuronal differentiation, and reduced purmorphamine to 0.1 μM since MNP differentiation required a low level of SHH (Saade et al., 2013). Meanwhile, CHIR, SB, and DMH1 were withdrawn from the medium because they were used to maintain MNP proliferation (Kalani et al., 2008).




Figure 2. Robust MNPs are derived in 12 days of iPSC differentiation

(A) Representative images of OLIG2⁺/NKX6.1⁺ MNPs generated in 12 days of differentiation.

(B) Representative images of OLIG2⁺/NKX2.2⁻ MNPs generated in 12 days of differentiation.

(C) The proportion of OLIG2⁺, NKX6.1⁺, and NKX2.2⁺ cells.

(D) RT-qPCR data showing relative expression of *OLIG2*, *NKX6.1*, *PAX6*, *NGN2*, and *PAX7* genes in 12-day culture compared to iPSCs. N = 2 cell lines, n = 3 replicates. All representative images were from the control line ALSH84C5, Scale bar, 100 μ m. See also Figure S3.

Following the next 6 days of exposure to 0.5 μ M RA + 0.1 μ M purmorphamine + 0.1 μ M Compound E + Neurotrophic factors (NTFs) (10 ng/mL each), cells exhibited typical neuronal morphology with long neurites and high expression of mature neuronal marker *MAP2* under both conditions (Figures S3D and S3E). The expression of MNP markers *OLIG2*, *HES5*, *NGN2*, *PAX6*, and *SOX2* was markedly repressed under both conditions, with greater reductions by adding Compound E from day 12, with the exception of *OLIG2* (Figure 3D). Surprisingly, only when Compound E was added from day 12, both MN-specific genes of *ISL1* and *MNX1* were induced; the addition of Compound E to day 9 MNPs induced *ISL1* but not *MNX1* expression (Figure 3E). Therefore, the timing of Compound E addition plays a crucial role in promoting MN differentiation.

We subsequently quantified the proportion of MNs on day 18 and consistently showed high efficiency of MN differentiation across 7 iPSC lines (Figure S3B). On day 18, 91.9% \pm 6.7% of ISL⁺, 86.7% \pm 6.1% of HB9⁺, 91.2% \pm 7.0% of CHAT⁺, and 96.8% \pm 6.8% of MAP2⁺ cells were identified (Figures 3F and 3G). Meanwhile, Ki67⁺ prolifer-

ating cells (1.28% \pm 0.95%) or OLIG2⁺ MNPs (3.37% \pm 2.87%) were rarely detected, and GFAP⁺ glia was absent (Figures S3C and S3D). In addition, high levels of mRNA expression were detected for synaptic excitatory markers (*SYN1*, *SHANK1*, and *PSD-95*), vesicular glutamate transporter (*VGlut2*), and glutamate receptor markers including ionotropic AMPA (*GRIA1* and *GRIA2*), NMDA (*GRIN1* and *GRIN2A*), and kainate (*GRIK1*) receptors (Figure S3E). Together, these data demonstrated that our protocol produced a high purity of sMNs with excitatory and glutamatergic properties on day 18 of iPSC differentiation.

The sMNs display a cervical MMC MN identity

During spinal cord patterning, sMNs acquire a diverse of positional and columnar characteristics, resulting in various subtypes of sMNs innervating different muscle groups in the body (Peljto and Wichterle, 2011; Philippidou and Dassen, 2013; Sagner and Briscoe, 2019). To construct clinically relevant *in vitro* disease models, it is crucial to determine the spatial identity of MNs because there is wide variation in illness onset sites among ALS patients.




Figure 3. Compound E effectively represses the expression of MNP genes and promotes the generation of sMNs

(A) Representative images of OLIG2⁺ MNPs on days 8, 10, and 12 of differentiation.

(B) A time course induction of *OLIG2* and *HES5* expression from day 6 to day 12 of differentiation. N = 3 cell lines, n = 3 replicates.

(C) Representative morphology of cells after 6 days of Compound E (Cpd E) treatment from day 9 or 12 of differentiation.

(D) Repression of MNP gene expression after 6 days of Cpd E treatment.

(E) The mRNA expression of MN-specific genes *ISL1*, *MNX1*, mature MN gene *CHAT*, and mature neuronal marker *MAP2* after 6 days of Cpd E treatment (MN stage) over that in their respective MNPs at day 9 or day 12. N = 3, n = 3.

(F) Representative images of ISL1⁺/MNX1⁺ and CHAT⁺/MAP2⁺ cells on day 18 under Cpd E treatment.

(G) The proportion of ISL1⁺, MNX1⁺, CHAT⁺, and MAP2⁺ cells among Hoechst-stained cells on day 18. N = 7, n = 2–3. All representative images were from the control line ALSH84C5, Scale bar, 100 μM. See also Figure S3.

During embryonic development, *HOX* genes are expressed in an overlapping rostrocaudal pattern from brain to the cervical, brachial, thoracic, and lumbar spinal cord (Figure 4A). Compared with iPSCs, *HOXB4*, *HOXC5* and *HOXC6* expression were significantly activated on day 18 sMNs, but not *HOXC8*, *HOXC9*, or *HOXC10* genes (Figure 4B). This *HOX* expression pattern confined the derived sMNs to the cervical region of the spinal cord, which was consistent with previous findings that RA and purmorphamine enabled cells to acquire a cervical character (Peljto et al., 2010; Wichterle et al., 2002).

To assess the columnar nature of iPSC-derived sMNs, we examined the expression of *FOXP1*, *LHX3*, and *POU3F1*, which are markers for hypaxial (HMC), medial (MMC), and phrenic motor column (PMC), respectively (Figure 4C).

FOXP1 and *POU3F1* expression were repressed during the course of MN differentiation, indicating the absence of HMC or PMC sMNs. Meanwhile, *LHX3* expression was steadily increased during the 4 weeks of differentiation in comparison with that in day 0 iPSCs (Figure 4D). This suggests that Compound E made no changes to the neuronal identity and the iPSC-derived sMNs belongs to the MMC subtype that innervate axial musculature.

Compound E accelerates functional maturation of iPSC-derived cervical sMNs

Variations in sMN differentiation protocols may lead to incomparable results among different studies (Du et al., 2015; Fujimori et al., 2018; Maury et al., 2015) (Figure S1).




Figure 4. The iPSC-derived sMNs resemble cervical MMC in the spinal cord

(A) Schematic diagram showing differential expression of *OTX2* and *HOX* genes in the hindbrain and spinal cord. Created with [BioRender.com](#) and adapted from [Philippidou and Dasen \(2013\)](#) and [Sagner and Briscoe \(2019\)](#).

(B) Expression of spinal cord positional markers of *HOXB4*, *HOXC5*, *HOXC6*, *HOXC8*, *HOXC9*, and *HOXC10* in day 0 iPSCs and day 18 iPSC-derived sMNs. $N = 3$, $n = 3$.

(C) Schematic diagram presenting MN columnar pattern, cell types, positions, general muscle targets, and specific marker genes. MMC neurons innervate axial muscles, HMC cells innervate hypaxial muscles, PMC neurons innervate diaphragm, LMC neurons innervate limb muscles, and preganglionic motor column (PGC) neurons innervate sympathetic ganglia. Adapted from [\(Peljto and Wichterle, 2011; Philippidou and Dasen, 2013\)](#) and created with [BioRender.com](#).


(D) The expression of *FOXP1*, *LHX3* and *POU3F1* mRNA during the course of differentiation. $N = 3$ cell lines, $n = 3$ replicates. nd, not detected, as the values were too small to be visible on the graph.

However, a standardized criterion can compensate for this deficiency if neuronal maturation is equivalent before phenotype comparison. Electrical activities and functional networks are essential characteristics of adult neurons. Therefore, we performed whole-cell patch clamp recordings on iPSC-derived sMNs on days 18 and 28 of differentiation. The cells on day 28 showed significantly greater electrophysiological maturity than those on day 18, as repeated action potentials (AP) were recorded in day 28 sMNs, but only single AP events were detected on day 18 (Figures 5A and 5B). Day 28 sMNs displayed input resistance of $546 \pm 62 \text{ M}\Omega$, Rheobase current of $10.7 \pm 2.3 \text{ pA}$, AP threshold of $-33.5 \pm 1.1 \text{ mV}$, and AP Amplitude of $29.0 \pm 2.5 \text{ mV}$, which appeared to be comparable with 18-week human fetal sMNs ([Tadros et al., 2015](#)) (Table S3). Moreover, they exhibited a voltage-dependent current, which was abolished by $0.5 \text{ }\mu\text{M}$ of the Na^+ channel blocker tetrodotoxin (TTX) or 30 mM of the K^+ channel blocker tetraethylammonium (TEA) (Figures 5C and 5D). The functional maturity of the sMNs were further supported by calcium imaging ex-

periments (Figures 5F–5Q). The iPSC-sMNs displayed spontaneous Ca^{2+} transients on both day 18 and 28 of differentiation (Figures 5F–5I). Additionally, day 28 sMNs were shown to be responsive to glutamate activation and CNQX blockade (Figures 5J–5Q).

Sporadic ALS-derived sMNs exhibit enhanced spontaneous intrinsic excitability

Altered excitability of MNs has previously been described in ALS patients ([Kanai et al., 2006; Vucic et al., 2008](#)), familial ALS-derived sMNs with known mutations ([Devlin et al., 2015; Naujock et al., 2016; Wainger et al., 2014](#)), and transgenic animal models ([Kuo et al., 2004; Pieri et al., 2003; van Zundert et al., 2008](#)). Although the affected CNS region varies with the progression of ALS, the detection of network and population electrophysiological properties in sALS iPSC-derived sMNs may provide insights into the underlying mechanism. We therefore replated day 12 MNPs onto the 48-well multi-electrode array (MEA) plates with 16 micro-electrodes/well. MEA recording was carried out every other day, before



(legend on next page)



medium change, from day 18 to day 48 of differentiation (Figure 6A). Consistent with the patch-clamp and Ca^{2+} imaging data, MEA recording detected significant spontaneous electrical activities on sMNs from day 20 or after, with extensive network activities on day 28 of differentiation, indicating formation of functional neuronal networks with extensive neurotransmission (Figure 6B).

During the time course of MEA recording, there was no significant difference in the number of active electrodes between the sALS (ALS69C4, ALS53C5, ALS57C1, and ALS57C4 lines) and the control group (ALSH84C5, ALSH47C1, and LQTH002C4) (Figure 6C), suggesting that sALS patient-derived iPSCs did not exhibit significant defects in MN differentiation or maturation. The sMNs from the patient group, however, fired significantly more spontaneous spikes, bursts, and network bursts than that in the control group, with an increased weighted mean firing rate (Figure 6D), burst frequency (Figure 6E), and network burst frequency (Figure 6F) from day 32 to day 48 of differentiation. The raw data for each donor are included in Table S3. These results indicate that the sALS samples exhibited elevated intrinsic excitability. Moreover, this hyperexcitability phenotype was phasic over time and became even more prominent in the late phases of sMN differentiation and during MN aging *in vitro*.

DISCUSSION

Numerous efforts have been made to differentiate human pluripotent stem cells into MNs for modeling MNDs. The research has, however, been hindered by the lengthy differentiation process, low efficiency, and extended maturation time to display functional properties (Figure S1). Here we have developed a novel monolayer MN induction protocol that enables derivation of nearly pure NSCs in 6 days, MNPs (73%–91%) in 12 days, cervical sMNs (88%–97%) in 18 days, and functionally mature sMNs in 28 days. These data were supported by comprehensive characterization

and functional assays. This protocol also enables phenotyping of pre-symptomatic changes of the disease in a relatively short duration, and we have identified hyper-excitability of sMNs derived from sALS iPSC lines via MEA recording after 32 days of differentiation.

One feature of our protocol is the monolayer-adherent culture. Serum-free floating embryoid body (EB) culture has been a default stage for neuronal differentiation in most previous MN differentiation protocols, as this was thought to mimic the three-dimensional environment *in vivo* (Table S1). However, the EB method can be accompanied with challenges including difficulty in observing cell morphology, variability in EB size, low permeability of morphogens to the innermost parts, and low cell viability after EB dissociation. The monolayer differentiation was explored previously, but ended up with a low efficiency of MNs or a lengthy maturation time (Bianchi et al., 2018; Qu et al., 2014) (Table S1). In this study, we demonstrate that monolayer culture together with timely addition of different molecules can result in up to 97% of CHAT^+ mature sMNs in 18 days of iPSC differentiation.

The MN development is governed by dorsal-ventral and anterior-posterior morphogens. We aimed to generate ventral sMNs and, therefore, used dual SMAD inhibition to repress dorsal pathways. Consequently, no expression of *PAX7* (a dorsal spinal marker) was detected. This was consistent with previous data that activation of the dorsal signaling by BMP4 was required to generate dorsal spinal interneurons from ESCs or iPSCs (Gupta et al., 2018; Ogura et al., 2018). Meanwhile, the iPSC-sMNs derived in this study showed cervical identity with high expression of *HOXB4*, *HOXC5*, and *HOXC6*, but no expression of *HOXC8*, *HOXC9*, or *HOXC10*. This is likely to result from the use of 0.1 μM RA during NSC-MNP transition. RA is essential to activate class I ventral transcription factors of *PAX6*, *DBX2*, *DBX1*, and *IRX3* (Patani, 2016). The endogenous RA at the cervical region is relatively low, as a two-tailed RA gradient is established with high concentration at the trunk mesoderm, which gradually declines anteriorly toward the hindbrain, and posteriorly toward the caudal

Figure 5. The iPSC-derived sMNs on day 28 show greater functional maturity

(A) Representative image of a patched sMN on day 28 of differentiation. Scale bar, 25 μm .

(B) Representative current-clamp recordings of iPSC-derived sMNs on day 18 ($n = 18$ neurons) and 28 ($n = 26$ neurons) of differentiation from the control ALSH47C1 line.

(C) Representative voltage-clamp recordings of a cell held at -70mV .

(D) Representative traces of the currents from the same cell as in (C) after the application of 0.5 μM Na^+ channel blocker TTX.

(E) Representative traces of the currents from the same cell as in (D) with 30 mM K^+ channel blocker TEA after TTX treatment.

(F–I) (F) Representative waterfall traces of spontaneous Ca^{2+} transients on day 18 (black) and 28 (red) from a 120-s recording. No significant difference in proportion (%) (G), frequency (Hz) (H), or the amplitude ($\Delta\text{F}/\text{F}_0$) (I) was shown on iPSC-derived sMNs between day 18 ($N = 4$ cell lines, $n = 12$ recordings/8 coverslips, 6,868 cells examined) and day 28 ($N = 4$, $n = 16/8$, 7,977 cells examined).

(J–Q) Representative waterfall traces and statistical results demonstrating the spontaneous Ca^{2+} transients and their responses to glutamate (Glu, 10 mM, [J–M], $N = 2$, $n = 4/4$, 2,143 cells examined) or CNQX (50 μM , [N–Q], $N = 2$, $n = 5/4$, 1,622 cells examined) on day 28.




Figure 6. The iPSC-derived sMNs from sALS patients exhibit an increased spontaneous firing

(A) Representative images of iPSC-derived day 28 sMNs on a 48-well MEA plate with 16 microelectrodes/well. Scale bar, 100 μ m.

(B) The MEA recording plot showing typical network firing patterns detected from iPSC-derived sMNs on day 28.

(C) The MEA recordings were carried out on iPSC-derived sMNs from day 18 to day 48. The control data were averaged from three lines of ALSH84C5, ALSH47C1, and LQTH002C4 of three independent donors, and patient data from four lines (ALS69C4, ALS53C5, ALS57C1, and ALS57C4) of three sALS patients.

(D–F) sMNs generated from patients ALS53, ALS57, and ALS69 had a significantly higher AP rate (weighted mean firing rate) (D), burst frequency (E), and network burst frequency (F) at the late stages of differentiation than the sMNs from the control group. The total MEA wells examined were $n = 22$ wells from $N = 3$ control iPSC lines, and $n = 15$ wells from $N = 4$ patient iPSC lines. The data were presented as mean \pm SEM. See also Table S3.

progenitor zone where FGF8 is highly expressed (Cunningham and Duester, 2015). A previous study also showed that 0.1 μ M RA could induce neural tube explants to express *Hoxc5* (cervical), but not *Hoxc8/9* (thoracic) or *Hoxc10* (lumbar) (Liu et al., 2001), whereas generation of lumbosacral sMNs requires addition of FGF8 in the absence of RA (Xu et al., 2023).

An SHH agonist, purmorphamine, is deployed in this protocol for ventralization and activation of class II transcription factors of *OLIG2*, *NKX6.1*, *NKX6.2*, and *NKX2.2* (Patani,

2016). During MN differentiation, *LHX3* interacts with *ISL1* and determines MN identity; however, in mature MNs, *LHX3* expression is retained exclusively in the MMC (Lee et al., 2012). The sMNs from this study exhibit MMC identity, as they increasingly express *LHX3* but not *FOXP1* or *POU3F1*. This is likely to result from the use of a medium-high concentration (0.5 μ M) of purmorphamine, as the pMN domain is anatomically the second domain most close to the floor plate, where SHH is most abundant, among the p0, p1, p2, pMN, and p3 domains (Andrews et al., 2019).



MMC sMNs innervate axial muscles in the neck, trunk, and hips, which are often deteriorated at the late stages of ALS progression. This may result in difficulties in head and neck control, balance, and stability, and decreased mobility (Duleep and Shefner, 2013). Cervical MNs at C2–C7 innervate respiratory muscles and axial muscle weakness is also linked to diaphragmatic denervation and disease progression, and consequently most ALS patients die of respiratory impairment (Cykowski et al., 2018; Niedermeier et al., 2019; Portaro et al., 2018). Atrophy of the cervical spinal cord is therefore used as a predictor of respiratory dysfunction (Cohen et al., 2017; Grolez et al., 2018; Patzig et al., 2019).

An ability to regenerate cervical sMNs is, therefore, vital for ALS, and we show here that the conversion of MNPs into cervical MMC MNs can be expedited by addition of 0.1 μ M Compound E, a γ -secretase and Notch inhibitor. Blocking of Notch signaling was shown to accelerate neuronal differentiation by delaying the G1/S phase transition (Borghese et al., 2010; Crawford and Roelink, 2007), but previous efforts were associated with low differentiation efficiency (<74% ISL1⁺/HB9⁺ cells) or a long duration (28–31 days) of CHAT⁺ MN generation (Du et al., 2015; Maury et al., 2015). We demonstrate that the timing of Compound E addition is crucial, and inhibition of γ -secretase on day 12 (not day 9) at the plateau stage of OLIG2 expression not only resulted in high CHAT⁺ sMN production (88%–97%) in 18 days, but also accelerated MN maturation, with multiple APs, extensive network activities, and strong calcium transients detected in day 28 sMNs.

Whereas the *bona fide* electrophysiological data of the adult human MNs is unavailable, our day 28 sMNs appeared to be comparable with 18-week human fetal MNs (Tadros et al., 2015) or iPSC-MNs in some other protocols (Table S3). Although reprogramming can be influenced by epigenetic memory and prolonged passaging (P20) may improve pluripotency (Koehler et al., 2011). Our seven iPSC lines at P20–30 showed similar capacity to generate NSCs (92%–98%), MNPs (73%–91%), sMNs (88%–97%), and comparable maturity at day 28. Replication of the protocol to derive sMNs from iPSCs of other ALS patients will provide independent cell models for investigating pathogenic mechanisms, particularly those associated with respiratory failure, as well as donor cells for subsequent preclinical and clinical trials, which may require a quantity of MNs. This may be done by expansion of MNPs as it was reported that OLIG2⁺ MNPs could be expanded for more than five passages without significantly losing MNP identity or capacity to generate sMNs (Du et al., 2015). Therefore, our monolayer sMN differentiation protocol, in combination with MNP expansion, may provide large quantities of cervical sMNs with consis-

tency and high maturity for large-scale studies, such as disease phenotyping, high-throughput drug screening, and future cell transplantation trials.

EXPERIMENTAL PROCEDURES

Resource availability

Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding authors, Sanbing Shen (sanbing.shen@universityofgalway.ie).

Materials availability

This study did not generate new unique reagents.

Data and code availability

No large datasets were generated in this study. No original code was generated in this study.

Cell culture and expansion

The iPSC lines used in this study are listed in Table S2 and have been characterized in previous studies (de la Cruz et al., 2020; Ge et al., 2020; Yang et al., 2019, 2020). All iPSC lines were maintained on Geltrex (A1413302, Gibco)-coated six-well plates in Essential 8 Flex Medium (A2858501, Gibco).

MN differentiation

The iPSCs at passages 20–30 were dissociated with Accutase (A6964, Sigma) and seeded at 30,000 cells/cm² on Geltrex-coated six-well plates in E8 with 10 μ M Y-27632 (72304, STEMCELL) on day –1. On day 0, E8 medium was switched to neuronal induction medium (NIM) consisting of 1:1 DMEM/F12 (BE-12-719F, Lonza) and neurobasal medium (21103049), 1% P/S (15140122), 0.5 \times N2 (17502048), 0.5 \times B27 (17504044), 0.1 mM ascorbic acid (AA, A4403, Sigma), and 1% GlutaMAX (35050061) from Gibco. The medium was renewed every other day with fresh 3 μ M CHIR (HY-10182, MCE), 2 μ M SB (HY-10431, MCE), and 2 μ M DMH1 (HY-12273, MCE) for 6 days. Cells were then split 1:3 onto Geltrex-coated plates in NIM with 1 μ M CHIR, 2 μ M SB, 2 μ M DMH1, 0.1 μ M RA (HY-14649, MCE), and 0.5 μ M purmorphamine (HY-15108, MCE) for the subsequent 6 days with medium changed every 2 days. On day 9 or 12, the patterned MNPs were re-seeded at 50,000 cells/cm² on 0.01% polyethyleneimine (PEI, P3143, Sigma)-coated plates for terminal differentiation. We added 0.5 μ M RA, 0.1 μ M purmorphamine, and 0.1 μ M Compound E (HY-14176, MCE) freshly for the subsequent 6 days into the NIM medium, consisting of Neurobasal plus medium (A358290, Gibco), 1% P/S, 0.5 \times N2, 0.5 \times B-27 Plus (A3582801, Gibco), 0.1 mM AA, and 1% GlutaMAX. The medium was half-changed every other day for 6 days, and small molecules were withdrawn from the culture medium from day 15 or day 18, respectively. NTFs of BDNF (450-02, PeproTech), IGF-1(450-13, PeproTech), and CTNF (450-10, PeproTech) were added at 10 ng/mL each, from day 9 or 12 onwards.

Immunocytochemistry

Cells were fixed with 4% paraformaldehyde (30525-89-4, Santa Cruz), permeabilized and blocked simultaneously in 1% BSA (A2153, Sigma) with 0.3% Triton X-100 (T8787, Sigma), and incubated with primary antibodies (Table S4) at 4°C overnight.



They were then washed, incubated with secondary antibodies and Hoechst 33258, imaged using a confocal microscope (Olympus FluoView 1000 system) or the Operetta High Content Imaging System (PerkinElmer), and quantified using ImageJ or the Operetta High Content Imaging System with Harmony software (PerkinElmer).

RNA extraction for RT-qPCR

Total RNA was extracted using RNeasy Plus Mini Kit (74134, Qiagen), and reverse transcribed to cDNA using SensiFAST cDNA Synthesis Kit (BIO-65053, Bioline). RT-qPCR was performed on a Step One Plus Real-Time PCR System (4376600, Applied Biosystems) using Fast SYBR Green Master Mix (4385612, Applied Biosystems). Primers are listed in [Table S4](#).

Whole-cell patch clamp

Patch clamp was performed as described previously with some modification ([Avazzadeh et al., 2021](#)). MNPs were seeded on 13-mm glass coverslips on day 12. Whole-cell patch clamp recordings were performed on day 18 ($n = 12$ neurons) and 28 ($n = 26$ neurons) in a warm extracellular bath solution (18°C–20°C), containing 135 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES sodium salt, and 10 mM glucose at pH 7.4 ([Wainger et al., 2014](#)). Patch pipettes were filled with intracellular solution containing 150 mM KCl, 6 mM MgCl₂, 10 mM HEPES, 1 mM EGTA (E3889, Sigma), 4 mM ATP (HY-B2176, MCE), 0.3 mM Na₂GTP (HY-12695, MCE), and 10 mM Na₂PhosCr (HY-D0885B, MCE) at pH 7.4 with a resistance of 2–3 MΩ. Images were captured using Zeiss Axiovert 200 (original magnification ×40).

Recordings were performed using an EPC10 patch-clamp amplifier from HEKA. Intrinsic firing properties of neurons were recorded in current-clamp mode, with step current injections from –40 to +100 pA in 10-pA increments. Voltage-dependent Na⁺ and K⁺ currents were recorded in voltage-clamp mode from a holding potential of –70 mV and step depolarization from –100 to +40 mV in 10-mV increments for 200 ms. Additional recordings were performed in the presence of 1 μM TTX (T-550, Alomone Labs) or 30 mM TEA (140023, Sigma) to block Na⁺ and K⁺ currents, respectively. All data were recorded as unfiltered voltage and current clamp recording at 50.0 kHz and 20.0 kHz, respectively.

Multi-electrode array assay

Approximately 50,000 MNPs in 8 μL NMM were plated on 0.1% PEI-coated CytoView 48-well MEA plate (M768-tMEA-48W, AXION) on day 12 of differentiation. Neuronal activities were recorded for 300 s every other day before medium change, from day 18 to day 48. In short, the 48-well MEA plate was docked into the Maestro MEA recording amplifier with a heater to maintain at 37°C (Axion Biosystems). Signals were sampled at 12.5 kHz, digitized and analyzed using Axion Integrated Studio Navigator (AxIS) 2.5.2 with a 200-Hz high-pass and 3-kHz low-pass filter. An adaptive spike detection threshold was set at 5.5 times of the standard deviation for each electrode with 1-s binning ([Wainger et al., 2014](#)).

The exported spike files (.spk) were batch-processed using Neural Metric Tool (Axion Biosystems). All data reflect well-wide averages from active electrodes, with the number of wells per condition rep-

resented by n values. Briefly, the active electrode was defined as having ≥ 5 spikes/min. The weighted Mean Firing Rate (Hz) was calculated as the total number of spikes divided by the number of active electrodes over a recording duration (300 s). A single electrode burst detector was set to detect the inter-spike interval (ISI) threshold with ≥ 5 spikes in a maximum of 100 ms ISI. Burst frequency was calculated as the total number of single-electrode bursts divided by the recording duration (300 s). The network burst detector was set to >50 spikes with a maximum of 100 ms of ISI, with $>35\%$ of active electrodes involved in bursting. The network burst rate was calculated as the total number of network bursts divided by the recording duration (300 s). The processed data were exported as a comma format.csv file. For comparison (i.e., time-course, control-patient pair), the.csv file was uploaded to the Axion Metric Plotting Tool. The summarized.csv file with parameters was exported for statistical analysis.

Calcium imaging

Calcium images was performed and analyzed as described previously ([Avazzadeh et al., 2019](#)).

Statistical analyses

Statistical analyses were performed with GraphPad Prism version 9.3.1 using paired or unpaired Student's t test with a level of significance set at * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$. N represents the total number of cell lines; n is the number of independent experiments. Data are presented as mean \pm SD or mean \pm SEM.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.stemcr.2023.07.004>.

AUTHOR CONTRIBUTIONS

Conceptualization: S.S., O.H., T.O., M.Y., and D.C.H.; experimental investigation: S.S., M.Y., and M.L.; data analysis: M.Y., M.L.G.Y., Y.L., and G.L.; Whole-cell patch-clamp and calcium imaging: Y.S., S.A., and L.Q.; original draft: M.Y. and M.L.; revision: S.S., O.H., T.O., D.C.H., G.Y., Y.L., G.L., and L.Q.

ACKNOWLEDGMENTS

We acknowledge volunteers for participating in this study. This research was supported by SFI Investigator award (13/IA/1787) and Center Grant Number 16/RC/3948, which was co-funded under the European Regional Development Fund and by FutureNeuro industry partners, Galway University Foundation, and the One Hundred Person Project of Hebei Province (E2019050021). This research was supported by the HRB-Clinical Research Facility Galway, a unit of the University of Galway and Saolta University Health Care Group, and with scientific and technical assistance of the NCBS Genomics Facility and the Center for Microscopy & Imaging, which are funded by the University of Galway and the Irish Government's Programme for Research in Third Level Institutions, Cycles 4/5, National Development Plan 2007–2013. The study was approved by the Clinical Research Ethics Committee of Galway University Hospitals (C.A.750).



CONFLICT OF INTERESTS

The authors declare no competing interests.

Received: March 12, 2023

Revised: July 17, 2023

Accepted: July 18, 2023

Published: August 17, 2023

REFERENCES

- Andrews, M.G., Kong, J., Novitch, B.G., and Butler, S.J. (2019). New perspectives on the mechanisms establishing the dorsal-ventral axis of the spinal cord. *Curr. Top. Dev. Biol.* *132*, 417–450.
- Avazzadeh, S., McDonagh, K., Reilly, J., Wang, Y., Boonkamp, S.D., McInerney, V., Krawczyk, J., Fitzgerald, J., Feerick, N., O'Sullivan, M., et al. (2019). Increased Ca(2+) signaling in NRXN1 α (+/-) neurons derived from ASD induced pluripotent stem cells. *Mol. Autism.* *10*, 52.
- Avazzadeh, S., Quinlan, L.R., Reilly, J., McDonagh, K., Jalali, A., Wang, Y., McInerney, V., Krawczyk, J., Ding, Y., Fitzgerald, J., et al. (2021). NRXN1 α (+/-) is associated with increased excitability in ASD iPSC-derived neurons. *BMC Neurosci.* *22*, 56.
- Ben-Shushan, E., Feldman, E., and Reubinoff, B.E. (2015). Notch signaling regulates motor neuron differentiation of human embryonic stem cells. *Stem Cells* *33*, 403–415.
- Bianchi, F., Malboubi, M., Li, Y., George, J.H., Jerusalem, A., Szele, F., Thompson, M.S., and Ye, H. (2018). Rapid and efficient differentiation of functional motor neurons from human iPSC for neural injury modelling. *Stem Cell Res.* *32*, 126–134.
- Borghese, L., Dolezalova, D., Opitz, T., Haupt, S., Leinhaas, A., Steinfarz, B., Koch, P., Edenhofer, F., Hampl, A., and Brüstle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. *Stem Cell* *28*, 955–964.
- Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., and Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* *27*, 275–280.
- Cohen, Y., Anaby, D., and Morozov, D. (2017). Diffusion MRI of the spinal cord: from structural studies to pathology. *NMR Biomed.* *30*, e3592.
- Crawford, T.Q., and Roelink, H. (2007). The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling. *Dev. Dynam.* *236*, 886–892.
- Cunningham, T.J., and Duester, G. (2015). Mechanisms of retinoic acid signalling and its roles in organ and limb development. *Nat. Rev. Mol. Cell Biol.* *16*, 110–123.
- Cykowski, M.D., Powell, S.Z., Appel, J.W., Arumanayagam, A.S., Rivera, A.L., and Appel, S.H. (2018). Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. *Acta Neuropathol. Commun.* *6*, 28.
- de la Cruz, B.M., Ding, Y., McInerney, V., Krawczyk, J., Lu, Y., Yang, G., Qian, X., Li, W., Howard, L., Allen, N.M., et al. (2020). Derivation of two iPSC lines from a sporadic ASD patient (NUIGi033-A) and a paternal control (NUIGi034-A). *Stem Cell Res.* *44*, 101722.
- De Robertis, E.M. (2006). Spemann's organizer and self-regulation in amphibian embryos. *Nat. Rev. Mol. Cell Biol.* *7*, 296–302.
- Devlin, A.C., Burr, K., Borooah, S., Foster, J.D., Cleary, E.M., Geti, I., Vallier, L., Shaw, C.E., Chandran, S., and Miles, G.B. (2015). Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. *Nat. Commun.* *6*, 5999.
- Du, Z.W., Chen, H., Liu, H., Lu, J., Qian, K., Huang, C.L., Zhong, X., Fan, F., and Zhang, S.C. (2015). Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. *Nat. Commun.* *6*, 6626.
- Duleep, A., and Shefner, J. (2013). Electrodiagnosis of motor neuron disease. *Phys. Med. Rehabil. Clin. N. Am.* *24*, 139–151.
- Fujimori, K., Ishikawa, M., Otomo, A., Atsuta, N., Nakamura, R., Akiyama, T., Hadano, S., Aoki, M., Saya, H., Sobue, G., and Okano, H. (2018). Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. *Nat. Med.* *24*, 1579–1589.
- Ge, N., Liu, M., Zhu, X., Krawczyk, J., McInerney, V., Shen, S., O'Brien, T., and Prendiville, T. (2020). Generation and characterization of two induced pluripotent stem cell lines (NUIGi038-A, NUIGi038-B) from dermal fibroblasts of a healthy individual. *Stem Cell Res.* *49*, 101996.
- Grolez, G., Kyheng, M., Lopes, R., Moreau, C., Timmerman, K., Auger, F., Kuchcinski, G., Duhamel, A., Jissendi-Tchofo, P., Besson, P., et al. (2018). MRI of the cervical spinal cord predicts respiratory dysfunction in ALS. *Sci. Rep.* *8*, 1828.
- Gupta, S., Sivalingam, D., Hain, S., Makkar, C., Sosa, E., Clark, A., and Butler, S.J. (2018). Deriving Dorsal Spinal Sensory Interneurons from Human Pluripotent Stem Cells. *Stem Cell Rep.* *10*, 390–405.
- Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E.M., Logroscino, G., Robberecht, W., Shaw, P.J., Simmons, Z., and van den Berg, L.H. (2017). Amyotrophic lateral sclerosis. *Nat. Rev. Dis. Primers* *3*, 17071.
- Jessell, T.M. (2000). Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nat. Rev. Genet.* *1*, 20–29.
- Kalani, M.Y.S., Cheshier, S.H., Cord, B.J., Bababegy, S.R., Vogel, H., Weissman, I.L., Palmer, T.D., and Nusse, R. (2008). Wnt-mediated self-renewal of neural stem/progenitor cells. *Proc. Natl. Acad. Sci. USA* *105*, 16970–16975.
- Kanai, K., Kuwabara, S., Misawa, S., Tamura, N., Ogawara, K., Nakata, M., Sawai, S., Hattori, T., and Bostock, H. (2006). Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. *Brain* *129*, 953–962.
- Koehler, K.R., Tropel, P., Theile, J.W., Kondo, T., Cummins, T.R., Viville, S., and Hashino, E. (2011). Extended passaging increases the efficiency of neural differentiation from induced pluripotent stem cells. *BMC Neurosci.* *12*, 82.



- Kuo, J.J., Schonewille, M., Siddique, T., Schults, A.N.A., Fu, R., Bär, P.R., Anelli, R., Heckman, C.J., and Kroese, A.B.A. (2004). Hyperexcitability of Cultured Spinal Motoneurons From Presymptomatic ALS Mice. *J. Neurophysiol.* *91*, 571–575.
- Lee, S., Cuvillier, J.M., Lee, B., Shen, R., Lee, J.W., and Lee, S.K. (2012). Fusion protein Isl1-Lhx3 specifies motor neuron fate by inducing motor neuron genes and concomitantly suppressing the interneuron programs. *Proc. Natl. Acad. Sci. USA* *109*, 3383–3388.
- Lee, S.K., Lee, B., Ruiz, E.C., and Pfaff, S.L. (2005). Olig2 and Ngn2 function in opposition to modulate gene expression in motor neuron progenitor cells. *Genes Dev.* *19*, 282–294.
- Lu, Q.R., Sun, T., Zhu, Z., Ma, N., Garcia, M., Stiles, C.D., and Rowitch, D.H. (2002). Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. *Cell* *109*, 75–86.
- Maurly, Y., Côme, J., Piskorowski, R.A., Salah-Mohellibi, N., Chevalleyre, V., Peschanski, M., Martinat, C., and Nedelec, S. (2015). Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. *Nat. Biotechnol.* *33*, 89–96.
- Muhr, J., Graziano, E., Wilson, S., Jessell, T.M., and Edlund, T. (1999). Convergent inductive signals specify midbrain, hindbrain, and spinal cord identity in gastrula stage chick embryos. *Neuron* *23*, 689–702.
- Muñoz-Sanjuán, I., and Brivanlou, A.H. (2002). Neural induction, the default model and embryonic stem cells. *Nat. Rev. Neurosci.* *3*, 271–280.
- Naujock, M., Stanslowsky, N., Bufler, S., Naumann, M., Reinhardt, P., Sternecker, J., Kefalakes, E., Kassebaum, C., Bursch, F., Lojewski, X., et al. (2016). 4-Aminopyridine Induced Activity Rescues Hypoexcitable Motor Neurons from Amyotrophic Lateral Sclerosis Patient-Derived Induced Pluripotent Stem Cells. *Stem cells (Dayton, Ohio)* *34*, 1563–1575.
- Niedermeyer, S., Murn, M., and Choi, P.J. (2019). Respiratory Failure in Amyotrophic Lateral Sclerosis. *Chest* *155*, 401–408.
- Nordström, U., Jessell, T.M., and Edlund, T. (2002). Progressive induction of caudal neural character by graded Wnt signaling. *Nat. Neurosci.* *5*, 525–532.
- Novitsch, B.G., Chen, A.I., and Jessell, T.M. (2001). Coordinate Regulation of Motor Neuron Subtype Identity and Pan-Neuronal Properties by the bHLH Repressor Olig2. *Neuron* *31*, 773–789.
- Ogura, T., Sakaguchi, H., Miyamoto, S., and Takahashi, J. (2018). Three-dimensional induction of dorsal, intermediate and ventral spinal cord tissues from human pluripotent stem cells. *Development* *145*, dev162214.
- Patani, R. (2016). Generating Diverse Spinal Motor Neuron Subtypes from Human Pluripotent Stem Cells. *Stem Cells Int.* *2016*, 1036974.
- Patani, R., Hollins, A.J., Wishart, T.M., Puddifoot, C.A., Alvarez, S., de Lera, A.R., Wyllie, D.J.A., Compston, D.A.S., Pedersen, R.A., Gillingwater, T.H., et al. (2011). Retinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state. *Nat. Commun.* *2*, 214.
- Patzig, M., Bochmann, K., Lutz, J., Stahl, R., Küpper, C., Liebig, T., Reilich, P., and Dieterich, M. (2019). Measurement of structural integrity of the spinal cord in patients with amyotrophic lateral sclerosis using diffusion tensor magnetic resonance imaging. *PLoS One* *14*, e0224078.
- Peljto, M., Dasen, J.S., Mazzoni, E.O., Jessell, T.M., and Wichterle, H. (2010). Functional Diversity of ESC-Derived Motor Neuron Subtypes Revealed through Intraspinal Transplantation. *Cell Stem Cell* *7*, 355–366.
- Peljto, M., and Wichterle, H. (2011). Programming embryonic stem cells to neuronal subtypes. *Curr. Opin. Neurobiol.* *21*, 43–51.
- Philippidou, P., and Dasen, J.S. (2013). Hox Genes: Choreographers in Neural Development, Architects of Circuit Organization. *Neuron* *80*, 12–34.
- Pieri, M., Albo, F., Gaetti, C., Spalloni, A., Bengtson, C.P., Longone, P., Cavalcanti, S., and Zona, C. (2003). Altered excitability of motor neurons in a transgenic mouse model of familial amyotrophic lateral sclerosis. *Neurosci. Lett.* *351*, 153–156.
- Portaro, S., Morini, E., Santoro, M.E., Accorinti, M., Marzullo, P., Naro, A., and Calabrò, R.S. (2018). Breathlessness in amyotrophic lateral sclerosis: A case report on the role of osteoporosis in the worsening of respiratory failure. *Medicine* *97*, e13026.
- Qu, Q., Li, D., Louis, K.R., Li, X., Yang, H., Sun, Q., Crandall, S.R., Tsang, S., Zhou, J., Cox, C.L., et al. (2014). High-efficiency motor neuron differentiation from human pluripotent stem cells and the function of Islet-1. *Nat. Commun.* *5*, 3449.
- Roelink, H., Porter, J.A., Chiang, C., Tanabe, Y., Chang, D.T., Beachy, P.A., and Jessell, T.M. (1995). Floor plate and motor neuron induction by different concentrations of the amino-terminal cleavage product of sonic hedgehog autoproteolysis. *Cell* *81*, 445–455.
- Saade, M., Gutiérrez-Vallejo, I., Le Dréau, G., Rabadán, M.A., Miguez, D.G., Buceta, J., and Martí, E. (2013). Sonic Hedgehog Signaling Switches the Mode of Division in the Developing Nervous System. *Cell Rep.* *4*, 492–503.
- Sagner, A., and Briscoe, J. (2019). Establishing neuronal diversity in the spinal cord: a time and a place. *Development* *146*, dev182154.
- Sagner, A., Gaber, Z.B., Delile, J., Kong, J.H., Rousso, D.L., Pearson, C.A., Weicksel, S.E., Melchionda, M., Mousavy Gharavy, S.N., Briscoe, J., and Novitsch, B.G. (2018). Olig2 and Hes regulatory dynamics during motor neuron differentiation revealed by single cell transcriptomics. *PLoS Biol.* *16*, e2003127.
- Shirasaki, R., and Pfaff, S.L. (2002). Transcriptional codes and the control of neuronal identity. *Annu. Rev. Neurosci.* *25*, 251–281.
- Stifani, N. (2014). Motor neurons and the generation of spinal motor neuron diversity. *Front. Cell. Neurosci.* *8*, 293.
- Tadros, M.A., Lim, R., Hughes, D.I., Brichta, A.M., and Callister, R.J. (2015). Electrical maturation of spinal neurons in the human fetus: comparison of ventral and dorsal horn. *J. Neurophysiol.* *114*, 2661–2671.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* *131*, 861–872.



- van Zundert, B., Peuscher, M.H., Hynynen, M., Chen, A., Neve, R.L., Brown, R.H., Constantine-Paton, M., and Bellingham, M.C. (2008). Neonatal Neuronal Circuitry Shows Hyperexcitable Disturbance in a Mouse Model of the Adult-Onset Neurodegenerative Disease Amyotrophic Lateral Sclerosis. *J. Neurosci.* *28*, 10864–10874.
- Vucic, S., Nicholson, G.A., and Kiernan, M.C. (2008). Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. *Brain* *131*, 1540–1550.
- Wainger, B.J., Kiskinis, E., Mellin, C., Wiskow, O., Han, S.S.W., Sandoe, J., Perez, N.P., Williams, L.A., Lee, S., Boulting, G., et al. (2014). Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. *Cell Rep.* *7*, 1–11.
- Wichterle, H., Lieberam, I., Porter, J.A., and Jessell, T.M. (2002). Directed differentiation of embryonic stem cells into motor neurons. *Cell* *110*, 385–397.
- Xu, H.J., Yao, Y., Yao, F., Chen, J., Li, M., Yang, X., Li, S., Lu, F., Hu, P., He, S., et al. (2023). Generation of functional posterior spinal motor neurons from hPSCs-derived human spinal cord neural progenitor cells. *Cell Regen.* *12*, 15.
- Yang, M., Liu, M., Ding, Y., Vajda, A., Ma, J., Cui, H., O'Brien, T., Henshall, D., Hardiman, O., and Shen, S. (2020). Generation of twelve induced pluripotent stem cell lines from two healthy controls and two patients with sporadic amyotrophic lateral sclerosis. *Stem Cell Res.* *44*, 101752.
- Yang, M., Liu, M., Vajda, A., O'Brien, T., Henshall, D., Hardiman, O., and Shen, S. (2019). Generation of six induced pluripotent stem cell (iPSC) lines from two patients with amyotrophic lateral sclerosis (NUIGi043-A, NUIGi043-B, NUIGi043-C, NUIGi044-A, NUIGi044-B, NUIGi044-C). *Stem Cell Res.* *40*, 101558.
- Zhou, Q., and Anderson, D.J. (2002). The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. *Cell* *109*, 61–73.

Stem Cell Reports, Volume 18

Supplemental Information

A novel protocol to derive cervical motor neurons from induced pluripotent stem cells for amyotrophic lateral sclerosis

Meimei Yang, Min Liu, Yajaira Feller Sánchez, Sahar Avazzadeh, Leo R. Quinlan, Gang Liu, Yin Lu, Guangming Yang, Timothy O'Brien, David C. Henshall, Orla Hardiman, and Sanbing Shen

Supplementary information

Figure S1




Figure S1. Comparison of Published sMN Differentiation Protocols. Ten protocols of iPSC-sMN differentiation were compared with respect to time (days in vitro). The end of the experiment (Assay) was based on the latest data presented in respective publications. KOSR, N2 and B27-A are the culture mediums. The abbreviations and full names are: BDNF – brain-derived neurotrophic factor, CHIR – CHIR99021, Compound C – a chemical inhibitor of Activin and BMP signalling, Compound E – a γ -secretase and notch pathway inhibitor, CNTF –Ciliary neurotrophic factor, DAPT – a notch response inhibitor, DMH1 – specific BMP-antagonist, Dorsomorphin (Dor, also called compound C) – a BMP inhibitor, FGF2 – Fibroblast growth factor 2, GDNF – glial cell line-derived neurotrophic factor, IGF-1 – Insulin-like Growth Factor 1, LDN193189 (LDN) – selective antagonist of BMP receptor, NT-3 – Neurotrophin-3,

Purmorphamine (PMN) – an SHH agonist, retinoic acid (RA), retinoic acid receptor (RAR)/retinoid X receptors (RXR), SAG – Sonic hedgehog signaling agonist, SB431542 (SB) - a TGF- β /SMAD inhibitor, SHH – Sonic Hedgehog. The right four columns listed a summary of results, including culture method (EB-embryoid body, indicating suspension culture and monolayer indicates adherent culture), induced action potentials (iAP), unique MN subtype markers observed which were expressed in the caudal spinal cord, including Hox family member C (HOXC9), Forkhead Box P1 (FOXP1), LIM Homeobox 3 (LHX3), and approximate yield of MNs which were based on the reported percentage of cells expressing HB9, ISL1 or CHAT.

Figure S2




Figure S2. The efficiency of NSC and MNP differentiation from multiple hPSC lines on day 6 and day 12. A) The proportion of NESTIN⁺, PAX6⁺, and SOX2⁺ cells on day 6 of differentiation. More than 600 cells from random fields were automatically counted by the Operetta High Content Imaging System in each cell line. **B) The efficiency of OLIG2⁺, NKX6.1⁺ and NKX2.2⁻ MNP differentiation from multiple hPSC lines on day 12. C)** Schematic showing the expression pattern of pMN domain markers in the developing spinal cord. Adapted from a reference (Sagner and Briscoe, 2019). Created with BioRender.com.

Figure S3.




Figure S3. Compound E can effectively drive the MNs to exit the cell cycle and convert OLIG2⁺ MNP to pure mature sMNs. **A)** Statistic analysis for the cells positive to OLIG2 from day 8 to day 12. N=3, n=3. **B)** The efficiency of ISL⁺, MNX1⁺, CHAT⁺, MAP2⁺, OLIG2⁺, Ki67⁺ sMN differentiation from multiple hPSC lines on day 18. **C)** Representative images of double staining of OLIG2/Ki67 in iPSC-derived sMNs on day 18. **D)** Representative images of single staining of GFAP and TUJ1 in iPSC-derived sMNs on day 18. Arrows indicate the unspecific staining of GFAP. **E)** RT-qPCR analysis of synaptic excitatory markers of *SYN1*, *SHANK1* and *PSD-95*, vesicular glutamate transporter *VGLUT2*, and glutamatergic neuronal markers, including ionotropic AMPA receptors of *GRIA1* and *GRIA2*, NMDA receptors of *GRIN2A*, kainate receptors of *GRIK1* in iPSC-derived sMNs on day 18 compared to iPSC on day 0. N=3. Scale bar, 100 μm.

Table S1. Small molecules for spinal MN induction.

Involved stage	Involved pathway	Name	Function	Reference	
Neural induction	Wnt activator	CHIR99021	Inhibit GSK3, Promote ectoderm generation and caudalization	(Du et al., 2015; Nordström et al., 2002)	
	Activin/TGFβ inhibitor	SB431542	Dual SMAD inhibition for neural induction	(Chambers et al. 2009)	
		BMP inhibitor		Noggin	(Chambers et al. 2009)
				DMH1	(Du et al., 2015)
				LDN	(Maury et al., 2015)
Compound C (Dorsomorphin)	Block both Activin/TGFβ and BMP pathway	(Zhou et al., 2010)			
MN caudalization	Retinoid acid	All trans-Retinoid acid	Caudalizing NSCs	(Chambers et al. 2009)	
MN ventralization	Sonic Hedgehog activator	SHH protein	Ventralizing NSCs	(Chambers et al. 2009)	
		SAG (SHH agonist)		(Gouti et al., 2014; Mak et al., 2012)	
		Purmorphamine (PMN, SHH agonist)		(Hu and Zhang, 2009; Mak et al., 2012)	
MN maturation	Notch pathway inhibitor	Compound E	Promote neurogenesis by inhibiting Notch signaling and repressing cell proliferation.	(Du et al., 2015)	
		DAPT		(Ben-Shushan et al., 2015; Maury et al., 2015)	

Table S2. Information of cell lines used in the study.

Status	Cell line	Sex	Age	Ethnicity
Healthy	NUIGi048-C (ALSH84C5)	29	Male	Caucasian
Healthy	NUIGi038-A (LQTH002C4)	47	Female	Caucasian
Healthy	NUIGi049-A (ALSH47C1)	66	Female	Caucasian
Sporadic ALS	NUIGi044-B (ALS69C4)	44	Male	Caucasian
Sporadic ALS	NUIGi050-A (ALS53C5)	60	Male	Caucasian
Sporadic ALS	NUIGi051-A (ALS57C1)	56	Female	Caucasian
Sporadic ALS	NUIGi051-C (ALS57C4)	56	Female	Caucasian